JPS56500138A - - Google Patents

Info

Publication number
JPS56500138A
JPS56500138A JP50067380A JP50067380A JPS56500138A JP S56500138 A JPS56500138 A JP S56500138A JP 50067380 A JP50067380 A JP 50067380A JP 50067380 A JP50067380 A JP 50067380A JP S56500138 A JPS56500138 A JP S56500138A
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP50067380A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19792910509 external-priority patent/DE2910509A1/de
Priority claimed from FR7906732A external-priority patent/FR2451194A1/fr
Application filed filed Critical
Publication of JPS56500138A publication Critical patent/JPS56500138A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50067380A 1979-03-16 1980-03-17 Pending JPS56500138A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19792910509 DE2910509A1 (de) 1979-03-16 1979-03-16 Teilchenfoermiges material fuer medizinische zwecke, verfahren zu seiner herstellung und seine verwendung als arzneimittel
FR7906732A FR2451194A1 (fr) 1979-03-16 1979-03-16 Nouveau medicament a base de ganglioside notamment pour le traitement du cholera, et compositions pharmaceutiques le contenant

Publications (1)

Publication Number Publication Date
JPS56500138A true JPS56500138A (ja) 1981-02-12

Family

ID=25778265

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50067380A Pending JPS56500138A (ja) 1979-03-16 1980-03-17

Country Status (5)

Country Link
US (1) US4347244A (ja)
EP (1) EP0016702B1 (ja)
JP (1) JPS56500138A (ja)
DE (1) DE3070189D1 (ja)
WO (1) WO1980001875A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02207089A (ja) * 1989-02-07 1990-08-16 Snow Brand Milk Prod Co Ltd 細菌毒素中和剤

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2478104B1 (fr) * 1980-03-17 1986-08-08 Merieux Inst Nouveaux derives de gangliosides, leur preparation et leur application
US4716223A (en) * 1981-08-04 1987-12-29 Fidia, S.P.A. Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
DE3379656D1 (en) * 1983-05-27 1989-05-24 Shanksville Corp N V Suppressing of graft rejection in organ transplantation
US4507472A (en) * 1983-06-14 1985-03-26 Usher Thomas C Manufacture of diethylaminoethyl dextrans
US4762822A (en) * 1985-08-08 1988-08-09 Ettinger Anna C Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
US4769362A (en) * 1985-10-01 1988-09-06 Trustees Of Boston University Increased vascular perfusion following administration of lipids
US4710490A (en) * 1985-10-01 1987-12-01 Angio Medical Corporation Compositions containing ganglioside molecules with enhanced angiogenic activity
US4990333A (en) * 1985-12-20 1991-02-05 Angio Medical Corporation Method for healing bone damage
GB8620361D0 (en) * 1986-08-21 1986-10-01 Windleshaw Enterprises Ltd Pharmaceutical compositions
IT1223408B (it) * 1987-12-09 1990-09-19 Crinos Industria Farmaco Procedimento per la preparazione di monosialoganglioside
US6407072B1 (en) * 1988-12-02 2002-06-18 Fidia S.P.A. Lysoganglioside derivatives
FR2640137A1 (fr) * 1988-12-08 1990-06-15 Texinfine Sa Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention
US5260280A (en) * 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
US5190925A (en) * 1989-06-08 1993-03-02 Fidia, S.P.A. Use of gangliosides in the treatment of autonomic dysfunction in Chagas' disease
DE69231675T2 (de) * 1991-10-18 2001-06-28 Synsorb Biotech Inc Behandlung bakterieller dysenterie
US5661131A (en) * 1995-06-05 1997-08-26 Synsorb Biotech, Inc. Treatment of cholera
US5811409A (en) * 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
DE19602108A1 (de) * 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
EP1903114A3 (en) 1997-12-01 2008-07-23 Neose Technologies, Inc. Enzymatic synthesis of gangliosides
US7220596B2 (en) * 1998-04-15 2007-05-22 Utah State University Real time detection of antigens
EP1068532A4 (en) 1998-04-15 2003-07-16 Univ Utah State DETECTION OF REAL-TIME ANTIGENS
US6699705B2 (en) 1999-02-01 2004-03-02 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
BRPI9903302B8 (pt) 1999-07-30 2021-07-06 Trb Pharma Ind Quimica E Farma processo para preparaÇço de um complexo de carvço-gm1, e, mÉtodo analÍtico para determinar gm1 nço derivado.
EP1435972B1 (en) 2001-08-29 2016-03-09 Seneb Biosciences Inc. Novel synthetic ganglioside derivatives and compositions thereof
US6869602B2 (en) * 2002-02-20 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells
US20040121406A1 (en) * 2002-05-23 2004-06-24 Wilson Constance Neely Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
US20120035120A1 (en) 2009-03-25 2012-02-09 Seneb Biosciences, Inc. Glycolipids as treatment for disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE610298A (ja) * 1960-11-17
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3627885A (en) * 1968-07-18 1971-12-14 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding
IT1046051B (it) * 1975-08-13 1980-06-30 Fidia Spa Nuova applicazione terapeutica dei gangliosidi e procedimento per la loro estrazione
FR2403081A1 (fr) * 1977-09-19 1979-04-13 Merieux Inst Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament
DE2840485A1 (de) * 1978-09-18 1980-03-27 Metzeler Kautschuk Drehschwingungsdaempfer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02207089A (ja) * 1989-02-07 1990-08-16 Snow Brand Milk Prod Co Ltd 細菌毒素中和剤
EP0385118A2 (en) 1989-02-07 1990-09-05 Snow Brand Milk Products Co., Ltd. Use of compounds containing or binding sialic acid to neutralize bacterial toxins

Also Published As

Publication number Publication date
DE3070189D1 (en) 1985-03-28
WO1980001875A1 (fr) 1980-09-18
EP0016702B1 (fr) 1985-02-20
EP0016702A1 (fr) 1980-10-01
US4347244A (en) 1982-08-31

Similar Documents

Publication Publication Date Title
DE3050975A1 (ja)
FR2446919B1 (ja)
JPS56500138A (ja)
BR8002583A (ja)
BR8006808A (ja)
FR2448535B1 (ja)
DE3046358C2 (ja)
FR2446256B1 (ja)
DE3034040C2 (ja)
FR2446867B1 (ja)
FR2448853B1 (ja)
FR2445788B1 (ja)
FR2446473B1 (ja)
AU78271S (ja)
BR5901094U (ja)
AU79826S (ja)
AU78270S (ja)
AU77669S (ja)
AU79918S (ja)
AU79950S (ja)
AU78386S (ja)
AU80228S (ja)
AU78385S (ja)
AU79559S (ja)
BG28664A1 (ja)